Trials / Completed
CompletedNCT01707472
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Simtuzumab | 700 mg intravenously for a total of 12 infusions. |
Timeline
- Start date
- 2012-10-04
- Primary completion
- 2014-10-17
- Completion
- 2014-10-17
- First posted
- 2012-10-16
- Last updated
- 2019-11-05
- Results posted
- 2019-10-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01707472. Inclusion in this directory is not an endorsement.